MOMA Therapeutics

MOMA Therapeutics, headquartered at 20 Acorn Park Drive, 6th Floor, Suite 600, Cambridge, MA 02140, is a pioneering biotechnology firm that has raised $150 million in Series B funding to advance its mission of discovering precision medicines. The company focuses on a target class-focused research approach, aiming to systematize drug discovery by identifying and targeting molecular machines that are fundamental to human diseases. To date, MOMA Therapeutics has identified over 400 molecular machines as potential therapeutic targets. The company employs a biomechanics engine that integrates various scientific disciplines including biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics to enhance its research and development efforts.